{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:45:21Z","timestamp":1793727921912,"version":"4.6.1"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.ejmech.2025.117372","type":"journal-article","created":{"date-parts":[[2025,2,5]],"date-time":"2025-02-05T11:21:41Z","timestamp":1738754501000},"page":"117372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Structure-based design, synthesis and biological evaluation of a novel d-amino acid-containing peptide inhibitor by blocking the RAD51-BRCA2 interaction for the treatment of kidney cancer"],"prefix":"10.1016","volume":"287","author":[{"given":"Jianjun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengnan","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao-Miao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117372_bib1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfae036","article-title":"Global epidemiology of kidney cancer","volume":"39","author":"Cirillo","year":"2024","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.ejmech.2025.117372_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/qua.27241","article-title":"Role of molecular descriptors in quantitative structure\u2010property relationship analysis of kidney cancer therapeutics","volume":"124","author":"Mahboob","year":"2024","journal-title":"Int. J. Quant. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib3","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/s41581-019-0210-z","article-title":"Oncometabolites in renal cancer","volume":"16","author":"Yong","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"10.1016\/j.ejmech.2025.117372_bib4","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13046-021-02114-2","article-title":"Current status of research on exosomes in general, and for the diagnosis and treatment of kidney cancer in particular","volume":"40","author":"Mao","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117372_bib5","volume":"vol. 40","author":"Mao","year":"2021"},{"key":"10.1016\/j.ejmech.2025.117372_bib6","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/carcin\/bgq064","article-title":"Homologous recombination in cancer development, treatment and development of drug resistance","volume":"31","author":"Helleday","year":"2010","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.ejmech.2025.117372_bib7","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.1349-7006.2007.00644.x","article-title":"Clinical relevance of the homologous recombination machinery in cancer therapy","volume":"99","author":"Miyagawa","year":"2008","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.117372_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/bcr310","article-title":"BRCA2 and homologous recombination","volume":"3","author":"Orelli","year":"2001","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117372_bib9","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/nsmb.2096","article-title":"Unraveling the mechanism of BRCA2 in homologous recombination","volume":"18","author":"Holloman","year":"2011","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ejmech.2025.117372_bib10","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1021\/acs.jmedchem.5b01762","article-title":"Development of small molecules that specifically inhibit the D-loop activity of RAD51","volume":"59","author":"Lv","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib11","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1021\/acs.biochem.7b00184","article-title":"Dss1 regulates association of Brh2 with Rad51","volume":"56","author":"Zhou","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.117372_bib12","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.dnarep.2007.12.008","article-title":"The consequences of Rad51 overexpression for normal and tumor cells","volume":"7","author":"Klein","year":"2008","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.117372_bib13","doi-asserted-by":"crossref","first-page":"20810","DOI":"10.1073\/pnas.0807990106","article-title":"Use of the Rad51 promoter for targeted anti-cancer therapy","volume":"105","author":"Hine","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.ejmech.2025.117372_bib14","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1186\/s12864-017-4026-6","article-title":"Unique protein expression signatures of survival time in kidney renal clear cell carcinoma through a pan-cancer screening","volume":"18","author":"Han","year":"2017","journal-title":"BMC Genom."},{"key":"10.1016\/j.ejmech.2025.117372_bib15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1007\/s00262-024-03681-x","article-title":"Dual-loss of PBRM1 and RAD51 identifies hyper-sensitive subset patients to immunotherapy in clear cell renal cell carcinoma","volume":"73","author":"Xu","year":"2024","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ejmech.2025.117372_bib16","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1093\/nar\/26.12.2859","article-title":"Overexpression of Rad51 protein stimulates homologous recombination and increases resistance of mammalian cells to ionizing radiation","volume":"26","author":"Visp\u00e9","year":"1998","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ejmech.2025.117372_bib17","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1016\/S0006-2952(02)00954-1","article-title":"Homologous recombinational repair vis-a-vis chlorambucil resistance in chronic lymphocytic leukemia","volume":"63","author":"Bello","year":"2002","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117372_bib18","doi-asserted-by":"crossref","first-page":"T1","DOI":"10.1530\/ERC-16-0297","article-title":"BRCA2 functions: from DNA repair to replication fork stabilization","volume":"23","author":"Fradet-Turcotte","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2025.117372_bib19","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1021\/acsmedchemlett.2c00063","article-title":"Identification of RAD51-BRCA2 inhibitors using N-Acylhydrazone-Based dynamic combinatorial chemistry","volume":"13","author":"Bagnolini","year":"2022","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.117372_bib20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S1097-2765(01)00175-7","article-title":"Role of BRCA2 in control of the RAD51 recombination and DNA repair protein","volume":"7","author":"Davies","year":"2001","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2025.117372_bib21","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1002\/1873-3468.12139","article-title":"Structure-activity relationship of the peptide binding-motif mediating the BRCA2:RAD51 protein-protein interaction","volume":"590","author":"Scott","year":"2016","journal-title":"FEBS Lett."},{"key":"10.1016\/j.ejmech.2025.117372_bib22","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/cmdc.201402428","article-title":"Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases","volume":"10","author":"Scott","year":"2015","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2025.117372_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.chembiol.2021.02.006","article-title":"A small-molecule inhibitor of the BRCA2-RAD51 interaction modulates RAD51 assembly and potentiates DNA damage-induced cell death","volume":"28","author":"Scott","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.117372_bib24","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1021\/acs.jmedchem.9b01526","article-title":"Synthetic lethality in pancreatic cancer: discovery of a new RAD51-BRCA2 small molecule disruptor that inhibits homologous recombination and synergizes with olaparib","volume":"63","author":"Bagnolini","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116114","article-title":"An 19F NMR fragment-based approach for the discovery and development of BRCA2-RAD51 inhibitors to pursuit synthetic lethality in combination with PARP inhibition in pancreatic cancer","volume":"265","author":"Myers","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib26","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1158\/1535-7163.MCT-17-1156","article-title":"A short BRCA2-derived cell-penetrating peptide targets RAD51 function and confers hypersensitivity toward PARP inhibition","volume":"17","author":"Trenner","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.117372_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1007\/s00018-007-7451-x","article-title":"The interface of protein-protein complexes: analysis of contacts and prediction of interactions","volume":"65","author":"Bahadur","year":"2008","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.117372_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/nrd.2016.29","article-title":"Small molecules, big targets: drug discovery faces the protein-protein interaction challenge","volume":"15","author":"Scott","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.117372_bib29","first-page":"11","article-title":"Current challenges and opportunities in designing protein-protein interaction targeted drugs","volume":"13","author":"Shin","year":"2020","journal-title":"Adv. Appl. Bioinform. Chem. : AABC"},{"key":"10.1016\/j.ejmech.2025.117372_bib30","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.tips.2013.04.007","article-title":"Targeting protein-protein interactions as an anticancer strategy","volume":"34","author":"Ivanov","year":"2013","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.117372_bib31","doi-asserted-by":"crossref","first-page":"11760","DOI":"10.1002\/anie.201506225","article-title":"Blocking of the PD-1\/PD-L1 interaction by a D-peptide antagonist for cancer immunotherapy","volume":"54","author":"Chang","year":"2015","journal-title":"Angewandte Chemie-International Edition"},{"key":"10.1016\/j.ejmech.2025.117372_bib32","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1126\/science.271.5257.1854","article-title":"Identification of D-peptide ligands through mirror-image phage display","volume":"271","author":"Schumacher","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2025.117372_bib33","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1002\/tcr.201600005","article-title":"D-peptides as recognition molecules and therapeutic agents","volume":"16","author":"Liu","year":"2016","journal-title":"Chem. Rec."},{"key":"10.1016\/j.ejmech.2025.117372_bib34","doi-asserted-by":"crossref","first-page":"14321","DOI":"10.1073\/pnas.1008930107","article-title":"D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms","volume":"107","author":"Liu","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.ejmech.2025.117372_bib35","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1073\/pnas.0407677102","article-title":"Partial D-amino acid substitution:: improved enzymatic stability and preserved Ab recognition of a MUC2 epitope peptide","volume":"102","author":"Tugyi","year":"2005","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.ejmech.2025.117372_bib36","article-title":"An NRP1\/MDM2-targeted D-peptide supramolecular nanomedicine for high-efficacy and low-toxic liver cancer therapy","volume":"10","author":"Zhou","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2025.117372_bib37","doi-asserted-by":"crossref","first-page":"7117","DOI":"10.1021\/jacs.1c12075","article-title":"Highly potent, selective, biostable, and cell-permeable cyclic D-peptide for dual-targeting therapy of lung cancer","volume":"144","author":"Zhou","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2025.117372_bib38","article-title":"A supramolecular nanomedicine based on bendamustine and MDM2-targeted D-peptide inhibitor for breast cancer therapy","volume":"10","author":"Zhou","year":"2021","journal-title":"Adv. Healthcare Mater."},{"key":"10.1016\/j.ejmech.2025.117372_bib39","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.2174\/1568026614666140929124445","article-title":"Structure-based virtual screening for drug discovery: principles, applications and recent advances","volume":"14","author":"Lionta","year":"2014","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib40","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1039\/c2cs35357a","article-title":"Drug repositioning by structure-based virtual screening","volume":"42","author":"Ma","year":"2013","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2025.117372_bib41","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2174\/156802609789207127","article-title":"Structure-based drug design strategies in medicinal chemistry","volume":"9","author":"Andricopulo","year":"2009","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib42","first-page":"779","article-title":"Virtual screening in structure-based drug discovery","volume":"4","author":"Barril","year":"2004","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib43","doi-asserted-by":"crossref","first-page":"7089","DOI":"10.1021\/acs.jmedchem.6b00261","article-title":"Discovery of novel polo-like kinase 1 polo-box domain inhibitors to induce mitotic arrest in tumor cells","volume":"59","author":"Qin","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117372_bib44","doi-asserted-by":"crossref","first-page":"4589","DOI":"10.1016\/j.jmb.2016.10.009","article-title":"Engineering archeal surrogate systems for the development of protein\u2013protein interaction inhibitors against human RAD51","volume":"428","author":"Moschetti","year":"2016","journal-title":"J. Mol. Biol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425001370?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425001370?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T06:03:42Z","timestamp":1759298622000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425001370"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":44,"alternative-id":["S0223523425001370"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117372","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-based design, synthesis and biological evaluation of a novel d-amino acid-containing peptide inhibitor by blocking the RAD51-BRCA2 interaction for the treatment of kidney cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"117372"}}